EMA Advises Against Use of Ivermectin for COVID-19 Outside of Clinical Trials

News
Article

The agency says that data do not support the use of ivermectin to prevent or treat COVID-19 outside of clinical trials.

The European Medicines Agency (EMA) announced on March 23, 2021 that use of ivermectin to prevent or treat COVID-19 outside of well-designed clinical trials is not supported by the data. EMA conducted a review of published laboratory studies, observational studies, clinical trials, and meta-analyses for ivermectin and found that current evidence was not sufficient to support the use of the drug outside clinical trials. According to the agency, laboratory studies showed that the drug could block SARS-CoV-2 replication but at higher concentrations than the currently authorized dose, and higher doses might increase side effects.

According to the agency, ivermectin is used to treat parasitic worm infestations and skin conditions such as rosacea. It is not authorized for use to prevent or treat COVID-19 in the European Union.

Source: EMA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes